• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

卵巢黏液性癌中的RAS突变

RAS Mutation in Mucinous Carcinoma of the Ovary.

作者信息

Panyavaranant Pinyada, Teerapakpinyo Chinachote, Pohthipornthawat Natkrita, Oranratanaphan Shina, Shuangshoti Shanop, Triratanachat Surang

机构信息

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital Bangkok, Thailand. Email:

Chulalongkorn GenePRO Center, Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

出版信息

Asian Pac J Cancer Prev. 2019 Apr 29;20(4):1127-1132. doi: 10.31557/APJCP.2019.20.4.1127.

DOI:10.31557/APJCP.2019.20.4.1127
PMID:31030485
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6948896/
Abstract

Objective: This study was designed to identify genetic mutation in mucinous carcinoma of the ovary of the patients in King Chulalongkorn Memorial hospital, Bangkok, Thailand and study the relationship between genetic mutation and patients’ prognosis. Methods: Fifty cases of primary mucinous carcinoma of the ovary were selected. DNA was analyzed for genetic mutation using ColoCarta Panel v1.0 and MassArray® System. Demographic data and clinical information of the participants were reviewed from electronic medical records and government data services. Results: Median of disease-free survival is 171.33 +/- 9.04 months and the median overall survival is 171.37 +/- 9.03 months. Twelve percent of the participants had recurrence and all of recurrent cases died from disease or its complication. We found three mutations which were KRAS (27 cases, 54%), PIK3CA (4 cases, 8%) and BRAF (1 case, 2%). Among the KRAS-mutated patients, the majority of the cases (25 cases, 92.6%) were in stage I. Recurrence and disease related mortality were not observed in the KRAS mutated patients. Conclusion: The genetic mutation analysis found three mutations which were KRAS 27 cases (54%), PIK3CA 4 cases (8%) and BRAF 1 case (2%) The ovarian mucinous carcinoma patients with KRAS mutation in our study showed excellent prognosis.

摘要

目的

本研究旨在鉴定泰国曼谷朱拉隆功国王纪念医院卵巢黏液性癌患者的基因突变情况，并研究基因突变与患者预后之间的关系。方法：选取50例原发性卵巢黏液性癌病例。使用ColoCarta Panel v1.0和MassArray®系统对DNA进行基因突变分析。从电子病历和政府数据服务中回顾参与者的人口统计学数据和临床信息。结果：无病生存期的中位数为171.33±9.04个月，总生存期的中位数为171.37±9.03个月。12%的参与者出现复发，所有复发病例均死于疾病或其并发症。我们发现了三种突变，即KRAS（27例，54%）、PIK3CA（4例，8%）和BRAF（1例，2%）。在KRAS突变患者中，大多数病例（25例，92.6%）处于I期。KRAS突变患者未观察到复发和疾病相关死亡率。结论：基因突变分析发现三种突变，即KRAS 27例（54%）、PIK3CA 4例（8%）和BRAF 1例（2%）。我们研究中KRAS突变的卵巢黏液性癌患者显示出良好的预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed3f/6948896/4f88eccc2961/APJCP-20-1127-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed3f/6948896/747980c8cbd1/APJCP-20-1127-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed3f/6948896/58f9b5425fc8/APJCP-20-1127-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed3f/6948896/081303f455a1/APJCP-20-1127-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed3f/6948896/4f88eccc2961/APJCP-20-1127-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed3f/6948896/747980c8cbd1/APJCP-20-1127-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed3f/6948896/58f9b5425fc8/APJCP-20-1127-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed3f/6948896/081303f455a1/APJCP-20-1127-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed3f/6948896/4f88eccc2961/APJCP-20-1127-g004.jpg

相似文献

1
RAS Mutation in Mucinous Carcinoma of the Ovary.卵巢黏液性癌中的RAS突变
Asian Pac J Cancer Prev. 2019 Apr 29;20(4):1127-1132. doi: 10.31557/APJCP.2019.20.4.1127.
2
Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.肺浸润性黏液腺癌的独特遗传和生存特征。
J Thorac Oncol. 2015 Aug;10(8):1156-62. doi: 10.1097/JTO.0000000000000579.
3
Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component.黏液分化的结直肠癌与 KRAS 或 BRAF 突变的高频发生相关，而与黏液成分的量无关。
BMC Cancer. 2020 May 8;20(1):400. doi: 10.1186/s12885-020-06913-2.
4
Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms.阑尾黏液性肿瘤中 TP53 突变的异质性突变特征和预后。
Hum Pathol. 2019 Mar;85:260-269. doi: 10.1016/j.humpath.2018.11.011. Epub 2018 Nov 17.
5
Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.原发部位真的重要吗？对来源不明的黏液性卵巢癌（MO-CUP）进行个体化治疗分析，以指导临床试验设计。
Gynecol Oncol. 2018 Sep;150(3):527-533. doi: 10.1016/j.ygyno.2018.07.013. Epub 2018 Jul 25.
6
Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.黏液性卵巢肿瘤的分子特征支持分层治疗方法，其中 19%的癌可针对 HER2 进行靶向治疗。
J Pathol. 2013 Jan;229(1):111-20. doi: 10.1002/path.4088.
7
Molecular characterization of 103 ovarian serous and mucinous tumors.103 例卵巢浆液性和黏液性肿瘤的分子特征分析。
Pathol Oncol Res. 2011 Sep;17(3):551-9. doi: 10.1007/s12253-010-9345-8. Epub 2010 Dec 7.
8
Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer.KRAS/BRAF/PIK3CA 基因突变在Ⅰ期结直肠癌中的临床影响和预后作用。
Dis Markers. 2018 Jun 19;2018:2959801. doi: 10.1155/2018/2959801. eCollection 2018.
9
KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.KRAS突变与接受辅助性FOLFOX治疗的III期或高危II期结肠癌患者的预后较差有关。
Ann Surg Oncol. 2015 Jan;22(1):187-94. doi: 10.1245/s10434-014-3826-z. Epub 2014 Jun 3.
10
Histological classification of mucinous ovarian tumors: inter-observer reproducibility, clinical relevance, and role of genetic biomarkers.黏液性卵巢肿瘤的组织学分类：观察者间的可重复性、临床相关性和遗传生物标志物的作用。
Virchows Arch. 2021 May;478(5):885-891. doi: 10.1007/s00428-020-02939-w. Epub 2020 Oct 3.

引用本文的文献

1
Molecular Histopathology for Establishing Diagnostic Method and Clinical Therapy for Ovarian Carcinoma.用于建立卵巢癌诊断方法和临床治疗的分子组织病理学
J Clin Med Res. 2023 Feb;15(2):68-75. doi: 10.14740/jocmr4853. Epub 2023 Feb 28.
2
Role of RAS signaling in ovarian cancer.RAS 信号通路在卵巢癌中的作用。
F1000Res. 2022 Nov 4;11:1253. doi: 10.12688/f1000research.126337.1. eCollection 2022.

本文引用的文献

1
Mutational heterogeneity in non-serous ovarian cancers.非浆液性卵巢癌中的突变异质性。
Sci Rep. 2017 Aug 29;7(1):9728. doi: 10.1038/s41598-017-10432-9.
2
Clinical, ultrasound parameters and tumor marker-based mathematical models and scoring systems in pre-surgical diagnosis of adnexal tumors.基于临床、超声参数及肿瘤标志物的数学模型和评分系统在附件肿瘤术前诊断中的应用
Ginekol Pol. 2016;87(12):824-829. doi: 10.5603/GP.2016.0096.
3
The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma.黏液性卵巢癌中 Her2 扩增和 Kras 突变的状态。
Hum Genomics. 2016 Dec 28;10(1):40. doi: 10.1186/s40246-016-0096-9.
4
Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.多点Kras癌基因突变可能提示整个黏液性卵巢肿瘤谱系中的黏液性癌。
Oncotarget. 2016 Dec 13;7(50):82097-82103. doi: 10.18632/oncotarget.13449.
5
KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.KRAS突变是早期肺腺癌的一个重要预后因素。
Am J Surg Pathol. 2016 Dec;40(12):1579-1590. doi: 10.1097/PAS.0000000000000744.
6
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.卵巢癌临床实践指南（2016 年版）.NCCN 肿瘤学临床实践指南
J Natl Compr Canc Netw. 2016 Sep;14(9):1134-63. doi: 10.6004/jnccn.2016.0122.
7
The molecular background of mucinous carcinoma beyond MUC2.黏液性癌的分子背景超出 MUC2。
J Pathol Clin Res. 2014 Nov 5;1(1):3-17. doi: 10.1002/cjp2.1. eCollection 2015 Jan.
8
Mucinous epithelial ovarian carcinoma.黏液性上皮性卵巢癌。
Ann Oncol. 2016 Apr;27 Suppl 1:i53-i57. doi: 10.1093/annonc/mdw087.
9
The Value of Preoperative CA 125 Levels in Prediction of Myometrial Invasion in Patients with Early-stage Endometrioid- type Endometrial Cancer.术前CA 125水平在早期子宫内膜样型子宫内膜癌患者子宫肌层浸润预测中的价值
Asian Pac J Cancer Prev. 2016;17(2):497-501. doi: 10.7314/apjcp.2016.17.2.497.
10
Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma.KRAS 和 BRAF 基因突变在小肠腺癌中的临床病理和预后相关性。
Mod Pathol. 2016 Apr;29(4):402-15. doi: 10.1038/modpathol.2016.40. Epub 2016 Feb 19.